Skip to main content

Table 3 Univariable and multivariable analyses for the risk factors of PGF or PT and survival post-transplantation

From: Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial

Parameters PGF/PT Overall survival Leukemia-free survival
Univariable HR (95%CI) P Multivariable HR (95%CI) P Univariable HR (95%CI) P Multivariable HR (95%CI) P Univariable HR (95%CI) P Multivariable HR (95%CI) P
Patient gender
male vs. female
0.796 (0.374–1.694)
0.554
- 0.459 (0.150–1.402)
0.171
- 0.751 (0.313–1.805)
0.523
-
Patient age
< 30y vs ≥ 30y (median)
1.136 (0.534–2.416)
0.741
- 0.083 (0.0011–0.638)
*0.017
0.091 (0.012–0.708)
*0.022
0.249 (0.083–0.746)
*0.013
0.321 (0.085–1.213)
0.094
Diagnosis
AML vs. ALL
0.804 (0.378–1.711)
0.572
- 0.736 (0.247–2.190)
0.581
- 1.030 (0.427–2.486)
0.947
-
Donor age
< 45y vs ≥ 45y (median)
0.635 (0.297–1.357)
0.242
- 1.411 (0.461–4.316)
0.546
- 1.92 (0.56–6.57)
0.300
-
HLA disparity
3/6vs.45/6
0.661 (0.289–1.511)
0.327
- 0.545 (0.168–1.733)
0.314
- 0.985 (0.329–2.949)
0.979
-
Donor gender
male vs. female
0.732 (0.329–1.629)
0.444
- 0.431 (0.145–1.283)
0.130
0.594 (0198–1.780)
0.352
0.545 (0.222–1.334)
0.184
 
Relationship
Parents vs. other
1.279 (0.593–2.756)
0.530
- 0.533 (0.174–1.630)
0.270
- 0.362 (0.139–0.943)
*0.038
0.645 (0.202–2.059)
0.459
ABO blood type
other vs. major mismatch
0.679 (0.287–1.606)
0.378
  0.366 (0.048–2.819)
0.335
- 0.224 (0.030–1.673)
0.145
0.205 (0.027–1.534)
0.123
CD34+ cell infused
≥ median vs.< median
0.429 (0.182–1.016)
0.054
0.400 (0.163–0.984)
*0.046
0.575 (0.177–1.868)
0.357
- 0.692 (0.276–1.735)
0.433
-
Chemo cycles before HSCT
<4 vs. ≥4 cycles
2.068 (0.905–4.724)
0.085
1.851 (0.798–4.293)
0.151
0.805 (0.270–2.399)
.696
- 1.423 (0.581–3.487)
0.440
-
Cycles to achieve CR
<2 vs. ≥2 cycles
1.014 (1.014–4.724)
0.978
  0.484 (0.149–1.572)
0.227
- 0.661 (0.2401–1.821)
0.424
-
NAC prophylaxis
NAC vs. high-risk control
*0.025
0.317 (0.113–0.890)
*0.021
*0.029
0.274 (0.096–0.777)
*0.015
0.463
1.064 (0.266–4.257)
0.930
- 0.792
1.028 (0.309–3.414)
0.964
-
NAC vs. low-risk control 0.643 (0.242–1.715)
0.373
0.725 (0.270–1.945)
0.523
2.150 (0.606–7.621)
0.236
- 1.378 (0.517–3.672)
0.521
-
  1. Abbreviations: AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, HLA human leukocyte antigen, HR hazard ratios, CI confidence interval, HSCT hematopoietic stem cell transplantation, chemo chemotherapy, CR complete remission, NAC N-acetyl-L-cysteine; *P< 0.05